Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
5 competitors in Myelodysplastic Syndromes
No patent data available. Pre-approval drugs may not have Orange Book listings.
Farydak
Farydak, in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent. Farydak, in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.
View on EMALeukemia, Myeloid, Chronic
Kidney Failure
Idiopathic Pulmonary Fibrosis
Ankylosing Spondylitis
Chronic Myeloid Leukemia